为了确保慢性髓细胞白血病（CML）患者的最佳护理，遵循酪氨酸激酶抑制剂（TKI）的规定已成为一个关键因素。本研究的目的是评估TKI依从性对接受TKI治疗的中国CML患者的临床结局的影响。本回顾性研究采用横断面设计，使用问卷调查评估398名CML患者对TKI的依从性。依从性使用Morisky药物依从性量表（MMAS-8）进行测量，将患者分为依从性低、中、高三组。在本研究的患者中，34.2%的患者被分类为高度依从性，43.2%和22.6%的患者被分类为中度和低度依从性。与低度依从性组相比，中度和高度依从性组的患者达到主要分子反应（MMR）的比例显著增加，并且切换TKI的比例显著降低。此外，未依从TKI治疗的患者在事件无进展生存和无失败生存方面表现出显著较低的水平，与高度依从性组相比。值得注意的是，定期分子监测和使用“CML学院”移动应用与增加TKI的依从性呈正相关。另一方面，接受三代以上一线TKI治疗的患者的依从性降低。研究结果表明，高度依从性的TKI治疗对CML患者具有临床效益。因此，在实际世界中，实施有效的指导和干预措施，以促进对TKI治疗的依从性，是至关重要的。版权所有 © 2023 Elsevier B.V. 保留所有权利。

To ensure optimal care for patients with chronic myeloid leukemia (CML), adherence to tyrosine kinase inhibitors (TKIs) has emerged as a critical component. The objective of this study was to assess the impact of TKIs adherence on clinical outcomes in a cohort of Chinese CML patients who received treatment with TKIs.This retrospective study employed a cross-sectional design utilizing questionnaires to assess adherence to TKIs in a sample of 398 patients diagnosed with CML. Adherence was measured using the Morisky Medication Adherence Scale (MMAS-8), which dichotomizes patients into low, medium, and high adherence groups.Of the patients included in this study, 34.2% were classified as highly adherent, with 43.2% and 22.6% of patients categorized as having medium and low adherence, respectively. Compared to the low-adherence group, patients in the medium- and high-adherence groups exhibited significantly higher rates of achieving major molecular response (MMR) and lower rates of switching TKIs. Moreover, patients who failed to adhere to TKIs treatment demonstrated significantly lower event-free survival and failure-free survival compared to those in the high-adherence group. Notably, regular molecular monitoring and utilization of the "CML Academy" mobile application were positively associated with increased TKI adherence. On the other hand, patients receiving third-generation or above first-line TKIs treatment displayed reduced adherence.The findings suggest that high adherence to TKIs treatment confers clinical benefits to patients with CML. Accordingly, the implementation of effective guidance and intervention measures aimed at promoting adherence to TKIs therapy in real-world settings is imperative.Copyright © 2023 Elsevier B.V. All rights reserved.